JILIN ZIXIN PHARMACEUTICAL INDUSTRIAL CO

Jilin Zixin Pharmaceutical Co., Ltd. was established in May 1998, is a research, development, production, sales, medicinal plant and animal species breeding of high-tech joint-stock enterprises. Since its inception, has been the modernization of Chinese medicine and modern medicine as the goal, dedicated to pharmaceutical research and development of new products at the same time, in strict accordance with the standards of production and procurement and supply, drug testing, technical innovation,... marketing, network and human resources development and other aspects to achieve scientific and modern management, has formed a certain core competitiveness of Chinese pharmaceutical value chain, the company in January 2007 passed the China Securities Regulatory Commission review, listed March 2, 2007 in Shenzhen Stock exchange , the stock short "purple Xin Pharmaceutical", stock code "002,118." Listed purple Xin Pharmaceutical, not only broke the past five years in Jilin enterprises in the A-share market IPO (initial public offering) of "Listed shortage" and fill the gaps in Jilin enterprises in Shenzhen SME board listed on. Zi Xin Pharmaceutical company has 11 wholly-owned subsidiaries, two subsidiaries and a joint stock company, are located in the Changbai Mountains in the South, Dong Lu, after ten years of rapid development, enterprises have been expanding , the output value of profits year after year. The company has been rated as large taxpayer non-public economy in Jilin Province; little giant enterprises; hundred non-public enterprises; Chinese medicine hundred companies nationwide; national paying technology companies; National Youth Civilization enterprises; national agricultural industrialization leading enterprises . In 2010, in response to the provincial government's call to increase the ginseng industry investment, carry out procurement of raw materials and processing of ginseng, Ginseng main producing areas around the establishment of a four ginseng production and processing base. Currently, there are 137, including food, cosmetics, health products, including varieties of ginseng products successfully developed, the first batch has approved 12 varieties, the second batch of 29, a total of 41 varieties approved pilot production. In addition, the company and the country more universities and research institutions to collaborate on research institutes in terms of ginseng, the role of research alliances through incubation, research cooperation with authoritative research institutes, mastered the "Ginseng cultivation", "do not eat ginseng angry "," ginseng residue off "and" bio-fermentation ginseng "and other core technology, and impose a global leader. Over the years, the purple Xin Pharmaceutical has been adhering to the "goods to Germany Shu brewing drug" business purpose, adhere to the "quality Zhi really pure," "respect knowledge, respect for science, traditional mining, and create new knowledge" business philosophy and approach. People-oriented, increase scientific and technological innovation and marketing efforts, and strive to cultivate high-quality workforce, a sound scientific management system; to efficiency, enhance the market adaptability and rapid response capability; carefully nurtured the company's brand, improve customer product satisfaction and brand loyalty. Future development goals purple Xin Pharmaceutical will also inherit and carry forward traditional Chinese medicine characteristics and advantages, adhere to market-oriented, resource-based, technology-driven, project construction as the focus, enhance the overall strength of the ginseng industry and market competitiveness, to revitalize Jilin ginseng, Chinese ginseng, and strengthen the protection of national industry and make due contributions, and toward science and technology, specialization, intensive pharmaceutical enterprise groups.More